Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/jcm10122697
Keywords
asthma; EBC; exhaled breath condensate; exhaled biomarkers; microbiota
Categories
Ask authors/readers for more resources
This paper provides an overview of the pathophysiology of asthma and the potential of exhaled breath condensate (EBC) as a source of biomarkers for lung disorders. It discusses the clinical implications and limitations of using EBC in asthma research.
The pathophysiology of asthma has been intensively studied, but its underlying mechanisms such as airway inflammation, control of airway tone, and bronchial reactivity are still not completely explained. There is an urgent need to implement novel, non-invasive diagnostic tools that can help to investigate local airway inflammation and connect the molecular pathways with the broad spectrum of clinical manifestations of asthma. The new biomarkers of different asthma endotypes could be used to confirm diagnosis, predict asthma exacerbations, or evaluate treatment response. In this paper, we briefly describe the characteristics of exhaled breath condensate (EBC) that is considered to be an interesting source of biomarkers of lung disorders. We look at the composition of EBC, some aspects of the collection procedure, the proposed biomarkers for asthma, and its clinical implications. We also indicate the limitations of the method and potential strategies to standardize the procedure of EBC collection and analytical methods.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available